Agios Pharmaceuticals Gestion
Gestion contrôle des critères 4/4
Le PDG Agios Pharmaceuticals est Brian Goff, nommé en Aug2022, a un mandat de 3.75 ans. La rémunération annuelle totale est $ 5.37M, composée du salaire de 15.8% et des bonus 84.2%, y compris les actions et options de la société. détient directement 0.31% des actions de la société, d'une valeur de $ 5.24M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.3 ans et 3.8 ans.
Informations clés
Brian Goff
Directeur général
US$5.4m
Rémunération totale
| Pourcentage du salaire du PDG | 15.77% |
| Durée du mandat du directeur général | 3.8yrs |
| Propriété du PDG | 0.3% |
| Durée moyenne d'occupation des postes de direction | 4.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.8yrs |
Mises à jour récentes de la gestion
Recent updates
AGIO: Sickle Cell FDA Path And Novo Readthroughs Will Shape Future Enthusiasm
Analysts have adjusted their outlook on Agios Pharmaceuticals with a modestly lower average price target, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E following recent mixed research, including several target cuts tied to Novo Nordisk related market views and earlier target hikes linked to potential regulatory catalysts for mitapivat. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a mix of optimism around potential regulatory catalysts for mitapivat and caution around market sizing and competitive readthroughs, particularly following data points tied to Novo Nordisk.Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade)
Apr 21AGIO: Sickle Cell Regulatory Uncertainty Will Continue To Restrain Enthusiasm
Analysts have raised their price target on Agios Pharmaceuticals by $3 to a new fair value estimate of $28, citing recent target increases from major firms and growing attention on upcoming regulatory and clinical catalysts. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a mix of optimism around upcoming regulatory events and ongoing caution around execution risks, valuation and timing of potential catalysts.
AGIO: Upcoming Regulatory Decisions In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have adjusted the fair value estimate for Agios Pharmaceuticals to $41.50 from $39.88, citing updated price targets and expectations tied to upcoming regulatory clarity on mitapivat, as well as broader support from recent research commentary. Analyst Commentary Recent Street research on Agios Pharmaceuticals centers on price target revisions, expectations around regulatory clarity for mitapivat in sickle cell disease, and the implications of the recent approval of Aqvesme.AGIO: Regulatory Clarity On Mitapivat In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have lifted the fair value estimate for Agios Pharmaceuticals by $1 to $39.88, citing higher price targets, expectations for regulatory clarity around mitapivat in sickle cell disease, and the recent approval of Aqvesme as key drivers of their updated outlook. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Agios Pharmaceuticals, with several price target revisions clustering in the US$25 to US$46 range and commentary centered on regulatory milestones, the impact of Aqvesme, and broader biotech sector conditions.AGIO: Thalassemia Decision And Recent Approval Will Drive Next Phase Upside
Analysts have nudged their intrinsic value estimate for Agios Pharmaceuticals higher to about $38.88 from $36.75, reflecting refreshed price targets in the $25 to $35 range and updated models following recent product approval and broader biotech sector tailwinds cited in recent research. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into the mid US$20s to mid US$30s, which aligns with the higher intrinsic value estimate around US$38.88 and indicates they see room for the shares to better reflect updated assumptions.AGIO: Sickle Cell Setback Will Continue To Restrain Enthusiasm Despite Thalassemia Approval
Analysts have lifted their fair value estimate for Agios Pharmaceuticals shares from $20 to $25, citing updated models that reflect recent drug approvals, ongoing FDA review milestones, and a series of higher Street price targets across the biotech sector. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a split view, with several bullish initiations and target hikes alongside more cautious revisions that highlight execution and growth risks around the company’s pipeline and commercial plans.AGIO: Thalassemia Decision And Aqvesme Approval Will Define Post RISE UP Upside
Narrative Update: Agios Pharmaceuticals (AGIO) Analysts have lifted Agios Pharmaceuticals' price targets into a US$25 to US$38 range, with recent tweaks to models reflecting the approval of Aqvesme, updated views on mitapivat and Pyrukynd, and a generally more constructive stance on U.S. biotech capital and deal activity. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a wide spread of views, with price targets clustered in the US$25 to US$38 range after earlier cuts from much higher levels.AGIO: Upcoming Thalassemia Decision Will Shape Post RISE UP Opportunity Narrative
Agios Pharmaceuticals’ fair value estimate edges up from US$36.00 to US$36.75 as analysts recalibrate models following recent target changes across the Street, reflecting updated views on Pyrukynd’s opportunity set, revised profit margin assumptions, and a higher future P/E multiple, despite some ongoing trial related uncertainties. Analyst Commentary Street research around Agios has become more divided, with some analysts leaning into the updated opportunity around Pyrukynd and other mitapivat indications, while others focus on execution risk and regulatory uncertainty following the RISE UP sickle cell disease data.AGIO: Upcoming FDA Thalassemia Decision Will Shape Post RISE UP Bullish Outlook
Analysts have lifted their aggregate fair value estimate for Agios Pharmaceuticals to $36.00 from $32.13, citing updated revenue and margin assumptions. This follows mixed views on the recent RISE UP data and new Street targets that range widely from US$20 to US$48, alongside Citi's fresh US$38 initiation and a near-term FDA catalyst watch.AGIO: Sickle Cell Setback Will Drive Cautious View Despite Upcoming FDA Decision
Analysts have cut their average price target on Agios Pharmaceuticals to $20 from $37, reflecting reduced expectations for mitapivat in sickle cell disease and more conservative long term revenue and expense assumptions, even as some still see upside around upcoming regulatory catalysts for Pyrukynd. Analyst Commentary Bearish analysts have responded to the RISE UP data by sharply recalibrating expectations for mitapivat in sickle cell disease, cutting price targets and, in some cases, ratings.AGIO: Upcoming FDA Decision Will Drive Bullish Outlook After Mixed Trial Data
Analysts have reduced their average price target on Agios Pharmaceuticals from about $42 to roughly $32 per share. This reflects higher perceived risk after mixed Phase 3 RISE UP data, tempered revenue and margin expectations, and a wider debate over the regulatory and commercial outlook for mitapivat and Pyrukynd across indications.AGIO: Regulatory Decisions Will Drive Outlook After Mixed Late-Stage Clinical Results
Agios Pharmaceuticals’ analyst price target has been reduced from approximately $47.50 to $42.33 per share. Analysts cite increased uncertainty for mitapivat in sickle cell disease following underwhelming Phase 3 trial results, as well as a more challenging regulatory and commercial pathway.FDA Approval And Global Partnerships Will Yield Mixed Prospects
Analysts modestly trimmed Agios Pharmaceuticals’ price target from $47.67 to $47.50, reflecting a brief FDA approval delay for Pyrukynd and cautious near-term modeling, while maintaining long-term conviction on the strength of clinical data and emerging commercial partnerships. Analyst Commentary Bullish analysts remain confident in FDA approval of Pyrukynd despite a three-month PDUFA delay due to the submission of a REMS for hepatocellular injury, which is viewed as a standard regulatory step and not due to new data requests.Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem
Feb 20
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Feb 14
Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges
Mitapivat's launch in thalassemia and sickle cell markets promises revenue growth from new opportunities, leveraging positive Phase III data for adoption.Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
Jan 14Agios Pharmaceuticals: A Long Overdue Follow Up
Dec 03We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$423m |
| Dec 31 2025 | US$5m | US$847k | -US$413m |
| Sep 30 2025 | n/a | n/a | -US$401m |
| Jun 30 2025 | n/a | n/a | US$650m |
| Mar 31 2025 | n/a | n/a | US$666m |
| Dec 31 2024 | US$7m | US$822k | US$674m |
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Rémunération vs marché: La rémunération totale de Brian ($USD 5.37M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.47M ).
Rémunération et revenus: La rémunération de Brian a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Brian Goff (56 yo)
3.8yrs
Titularisation
US$5,370,389
Compensation
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. since June 2024. He has been Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. since August 08, 2022. He...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$5.37m | 0.31% $ 5.2m | |
| Chief Financial Officer | 3.7yrs | US$2.52m | 0.094% $ 1.6m | |
| Chief Legal Officer | 4.3yrs | US$2.37m | 0.084% $ 1.4m | |
| Chief Corporate Development & Strategy Officer | 1.2yrs | US$2.81m | 0.018% $ 292.2k | |
| Chief Medical Officer and Head of Research & Development | 4.7yrs | US$2.09m | 0.14% $ 2.3m | |
| Co-Founder | no data | US$333.51k | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| VP, Controller & Principal Accounting Officer | 4.8yrs | pas de données | 0.0015% $ 24.6k | |
| Chief Technical Operations Officer | 8.9yrs | pas de données | pas de données | |
| Vice President of Investor Relations | no data | pas de données | pas de données |
4.3yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: L'équipe de direction de AGIO est considérée comme expérimentée (ancienneté moyenne 4.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$5.37m | 0.31% $ 5.2m | |
| Chair of the Board of Directors | 8.4yrs | US$492.16k | 0.26% $ 4.3m | |
| Independent Director | 2.9yrs | US$469.66k | 0.010% $ 172.5k | |
| Lead Independent Director | 11.4yrs | US$498.41k | 0.013% $ 212.3k | |
| Independent Director | less than a year | US$657.15k | pas de données | |
| Independent Director | 10.9yrs | US$464.66k | 0.029% $ 484.1k | |
| Independent Director | 3.8yrs | US$467.16k | 0.021% $ 352.9k | |
| Independent Director | 3.8yrs | US$467.16k | 0.021% $ 352.9k | |
| Independent Director | 9yrs | US$469.66k | 0.030% $ 500.2k | |
| Independent Director | 2.9yrs | US$458.41k | 0.010% $ 172.5k |
3.8yrs
Durée moyenne de l'emploi
62yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de AGIO sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/01 15:19 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Agios Pharmaceuticals, Inc. est couverte par 29 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |